rhegfr fc  (R&D Systems)

Journal: Biomolecules

Article Title: A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice.

doi: 10.3390/biom15040471

Figure Lengend Snippet: Figure 1. Cell labeling efficiency of the bispecific B10–B11 Nanofitin and its cytotoxic effect on the A431 on tumor cell line. (A) Cell labeling efficiency evaluation by flow cytometry of B10, B11, and bispecific B10–B11 Nanofitins on A431 cell line. Dotted lines represent alignment with the isotype control. (B) Expression level of programmed death-ligand 1 (PD-L1) (left) and Epithelial Growth Factor Receptor (EGFR) (right) on the A431 cell line. In grey: isotype control; in black: anti-PD-L1 or anti-EGFR antibody. (C) The real-time proliferation of A431 cells co-cultured with Jurkat cells exhibiting background activity. In black: A431 cells co-cultured with a mix of Jurkat cells and anti-EpCAM x CD3 BiTE without Nanofitin treatment; in red: A431 cells co-cultured with a mix of Jurkat cells and anti-EpCAM x CD3 BiTE and treated by the B11 Nanofitin (10 µM); in purple: A431 cells co-cultured with a mix of Jurkat cells and anti-EpCAM x CD3 BiTE and treated by the B10–B11 Nanofitin (10 µM). Significance was assessed by two-way ANOVA using 6 Prism software (GraphPad). **** p < 0.0001 (n = 3). (D) The real-time proliferation of A431 cells. In black: A431 cells alone; in red: A431 cells treated by the B11 Nanofitin (10 µM); in purple: A431 cells treated by the B10–B11 Nanofitin (10 µM). Significance was assessed by two-way ANOVA using 6 Prism software (GraphPad). NS: not significant (n = 3).

Article Snippet: The binding kinetic parameters of Nanofitins were defined by loading of 10 μg/mL mouse EGFR Fc chimera protein (#1280-ER-050, R&D Systems, Minneapolis, MN, USA) and 5 μg/mL recombinant mouse PDL1/B7-H1 Fc chimera protein (#1019-B7-100, R&D Systems) at 2 nm on protein A biosensors (#18-5012, Sartorius).

Techniques: Labeling, Flow Cytometry, Control, Expressing, Cell Culture, Activity Assay, Software

Journal: Biomolecules

Article Title: A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice.

doi: 10.3390/biom15040471

Figure Lengend Snippet: Figure 3. Mouse cross-reactivity of the bispecific B10–B11 Nanofitin. (A) Expression level of PD-L1 (left) and EGFR (right) on CT26 cell line. In grey: isotype control; in black: anti-PD-L1 or EGFR antibody. (B) Biolayer interferometry sensorgrams and binding kinetic parameters of monomeric B10 and B11 Nanofitins and bispecific B10–B11 Nanofitin on mouse EGFR and PD-L1. Fittings (1:1 model) are represented as solid gray lines. (C) CT26 cell labeling efficiency evaluation by flow cytometry of monomeric B10 and B11 and bispecific B10–B11 Nanofitins. Dotted lines represent alignment with the isotype control.

Article Snippet: The binding kinetic parameters of Nanofitins were defined by loading of 10 μg/mL mouse EGFR Fc chimera protein (#1280-ER-050, R&D Systems, Minneapolis, MN, USA) and 5 μg/mL recombinant mouse PDL1/B7-H1 Fc chimera protein (#1019-B7-100, R&D Systems) at 2 nm on protein A biosensors (#18-5012, Sartorius).

Techniques: Expressing, Control, Binding Assay, Labeling, Flow Cytometry